Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

My battle with Kaiser Healthcare ....and what

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (17) | Next 10 | Previous | Next
Whalatane Member Profile
Followed By 47
Posts 10,992
Boards Moderated 0
Alias Born 06/13/11
160x600 placeholder
European Medicines Agency Accepts for Review Marketing Authorization Application for Amarin’s Icosapent Ethyl (Vascepa®) f... GlobeNewswire Inc. - 12/2/2019 6:00:10 AM
Amarin Highlights Key REDUCE-IT®-Related Data Presented at American Heart Association 2019 Scientific Sessions GlobeNewswire Inc. - 11/18/2019 5:30:00 PM
Amarin’s John Thero Awarded EY Entrepreneur of The Year® 2019 Life Sciences National Award GlobeNewswire Inc. - 11/18/2019 12:15:12 PM
Amarin Announced FDA Advisory Committee Voted Unanimously (16-0) to Recommend Approval of Vascepa® (icosapent ethyl) Capsule... GlobeNewswire Inc. - 11/14/2019 5:34:37 PM
Amarin Corporation plc (NASDAQ:AMRN) Stock Trading Halted Today for Scheduled FDA Advisory Committee Review of sNDA Seeking N... GlobeNewswire Inc. - 11/14/2019 6:59:25 AM
New Analysis Shows Icosapent Ethyl (Vascepa®) Is Cost Effective and Offers Rare Finding of Better Outcomes at Lower Healthca... GlobeNewswire Inc. - 11/11/2019 1:19:57 PM
REDUCE-IT® USA Results, in Prespecified Subgroup Analyses of Landmark REDUCE-IT Global Study, Showed Robust Cardiovascular R... GlobeNewswire Inc. - 11/11/2019 6:30:48 AM
Amarin to Present at the Jefferies 2019 London Healthcare Conference GlobeNewswire Inc. - 11/11/2019 5:00:00 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 11/5/2019 5:29:19 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/5/2019 6:37:28 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2019 6:31:38 AM
Amarin Reports Third Quarter 2019 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 11/5/2019 5:00:00 AM
Seven Data Presentations Relevant to Vascepa® (Icosapent Ethyl) Capsules and Persistent Cardiovascular Risk to be Presented ... GlobeNewswire Inc. - 11/4/2019 6:00:00 AM
Amarin to Report Third Quarter 2019 Results and Host Conference Call on November 5, 2019 GlobeNewswire Inc. - 10/24/2019 4:30:05 PM
On Watch this Week with Near-Term Potential Catalysts InvestorsHub NewsWire - 10/21/2019 8:00:00 AM
Independent Drug-Pricing Assessment Finds Vascepa® (icosapent ethyl) Cost-Effective as an Adjunct to Statins in Treating Pat... GlobeNewswire Inc. - 10/17/2019 9:49:02 AM
Amarin to Participate in the Cantor Global Healthcare Conference GlobeNewswire Inc. - 9/23/2019 4:15:00 PM
National Lipid Association’s New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognize... GlobeNewswire Inc. - 9/16/2019 6:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/12/2019 6:14:02 AM
New 2019 Updates to the European Society of Cardiology’s and European Atherosclerosis Society’s Guidelines for the Manage... GlobeNewswire Inc. - 9/3/2019 6:00:00 AM
Amarin to Participate in the H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire Inc. - 8/28/2019 6:00:00 AM
Amarin Provides Overview on Growing Global Attention on REDUCE-IT™ Results and Cardiovascular Risk Management Beyond Choles... GlobeNewswire Inc. - 8/27/2019 6:00:00 AM
Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference GlobeNewswire Inc. - 8/21/2019 6:00:00 AM
Amarin (AMRN) Alert: Johnson Fistel Launches Investigation into Amarin Corporation plc; Investors Encouraged to Contact Firm PR Newswire (US) - 8/9/2019 8:53:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/9/2019 7:22:13 AM
Whalatane   Monday, 09/16/19 03:25:31 PM
Re: None
Post # of 232361 
My battle with Kaiser Healthcare ....and what to be ready for at Adcom.

I've been talking to other MD's re a new prescription for Vascepa ...so far its more complicated then I expected .
This post is not about that .

This post is a request for help in responding to the following from my Kaiser Cardiologist .....after I had sent him the NLA statement

His response
"The trial has problems, there was an increase of atrial fibrillation in the treatment group, and in the control group mineral oil was used which could have had an adverse effect.
I can't recommend this medication at this time.
The FDA currently recommends it only for patients for severe hypertriglyceridemia, triglycerides of 500 mg/dl, typically they make recommendations,on more than one trial. "


Can anyone link specific responses to his concerns
1) Increase in A Fib ...from what I remember there was no increase in strokes
2) Mineral oil ....does anyone remember the specific Dr Bhatt or AMRN response to that .
3) FDA wanting more than 1 trial

I know the easiest thing to do is probably dump Kaiser and try and sign up with UCSF ...but there are problems with that since my Medicare is apparently tied to Kaiser until the Nov " open enrollment " period ...my brief understanding .
Switching is probably the easiest ....but I'm inclined to want to fight Kaiser .....mount a "patient advocate "campaign...so any suggestions on how I might do that would be welcome .

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (17) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist